Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2011

01-10-2011 | Melanomas

Selective Sentinel Lymph Node Dissection for Melanoma: Importance of Harvesting Nodes with Lower Radioactive Counts without the Need for Blue Dye

Authors: Liang-Chih Liu, MD, Brian M. Parrett, MD, Tyler Jenkins, BA, Wayne Lee, MD, Eugene Morita, MD, Patrick Treseler, MD, Laura Huang, BS, Suresh Thummala, MD, Robert E. Allen, MD, Mohammed Kashani-Sabet, MD, Stanley P. L. Leong, MD

Published in: Annals of Surgical Oncology | Issue 10/2011

Login to get access

Abstract

Background

Determining how many sentinel lymph nodes (SLNs) should be removed for melanoma is important. The purpose of this study is to determine the frequency at which nodes that are less radioactive than the “hottest” node (which is negative) are positive for melanoma, how low of a radioactivity should warrant harvest, and if isosulfan blue is necessary.

Methods

We reviewed 1,152 melanoma patients who underwent lymphoscintigraphy with technetium, with or without blue dye, and SLN dissection from 1996 to 2008. SLNs with radioactivity ≥10% of the “hottest” SLN, all blue nodes, and all suspicious nodes were removed and analyzed. The miss rate was calculated as the proportion of node positive cases in which the “hottest” SLN was negative.

Results

SLNs were identified in 1,520 nodal basins in 1,152 patients. SLN micrometastases were detected in 218 basins (14%) in 204 patients (18%). In 16% of SLN-positive patients (33/204 patients), the positive SLN was found to have a lower radioactive count than the “hottest” SLN, which was negative. In 21 of these cases, the positive SLNs had radioactivity ≤50% of the “hottest” SLN. The 10% rule significantly reduced the miss rate to 2.5% compared with removal of only the “hottest” SLN (miss rate = 16%). Also, blue dye did not significantly decrease the miss rate compared with radiocolloid alone using the 10% rule.

Conclusions

To decrease the miss rate, all SLNs with ≥10% of the ex vivo radioactivity of the “hottest” SLN should be removed and blue dye is not essential.
Literature
1.
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMed
2.
Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759–67.PubMedCrossRef
3.
Satzger I, Meier A, Hoy L, Völker B, Kapp A, Hauschild A, Gutzmer R. Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. Ann Surg Oncol. 2010;Sep 14 [Epub ahead of print].
4.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:976–83.PubMed
5.
Leong SP. Sentinel lymph node mapping and selective lymphadenectomy: the standard of care for melanoma. Curr Treat Options Oncol. 2004;5:185–94.PubMedCrossRef
6.
Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009;60:872–5.PubMedCrossRef
7.
Bartolomei M, Testori A, Chinol M, et al. Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. Eur J Nucl Med. 1998; 25:1489–94.PubMedCrossRef
8.
Gershenwald JE, Tseng CH, Thompson W, et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998;124:203–10.PubMedCrossRef
9.
Leong SP, Donegan E, Heffernon W, et al. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–6.PubMedCrossRef
10.
Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg. 2002;95:385–8.PubMed
11.
McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001;8:192–7.PubMedCrossRef
12.
Porter GA, Ross MI, Berman RS, et al. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? Surgery. 2000;128:306–11.PubMedCrossRef
13.
Carlson GW, Murray DR, Thourani V, Hestley A, Cohen C. The definition of the sentinel lymph node in melanoma based on radioactive counts. Ann Surg Oncol. 2002;9:929–33.PubMedCrossRef
14.
Chagpar AB, Scoggins CR, Martin RC II, et al. Are 3 sentinel nodes sufficient? Arch Surg. 2007;142:456–9.PubMedCrossRef
15.
Scoggins CR, Martin RC, Ross MI, et al. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010;17:709–17.PubMedCrossRef
16.
Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–11.PubMed
17.
Cox CE, Salud CJ, Cantor A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg. 2001;193:593–600.PubMedCrossRef
18.
Ross GL, Shoaib T, Scott J, Soutar DS, Gray HW, MacKie R. The learning curve for sentinel node biopsy in malignant melanoma. Br J Plast Surg. 2002;55:298–301.PubMedCrossRef
19.
Testori A, Bartolomei M, Grana C, et al. Sentinel node localization in primary melanoma: learning curve and results. Melanoma Res. 1999;9:587–93.PubMedCrossRef
20.
Kroon HM, Lowe L, Wong S, et al. What is a sentinel node? re-evaluating the 10% rule for sentinel lymph node biopsy in melanoma. J Surg Oncol. 2007;95:623–8.PubMedCrossRef
21.
Sagebiel RW. The pathology of melanoma as a basis for prognostic models: The UCSF Experience. Pigment Cell Res. 1994;7:101–3.PubMedCrossRef
22.
Treseler PA, Tauch PS. Pathologic analysis of the sentinel lymph node. Surg Clin North Am. 2000;80:1695–719.PubMedCrossRef
23.
Liu LC, Lang JE, Jenkins T, et al. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg. 2008;207:853–8.PubMedCrossRef
24.
Cody HS. Sentinel lymph node mapping in breast cancer. Oncology. 1999;13:25–34.PubMed
25.
Soni M, Saha S, Koran A, et al. A prospective trial comparing 1% lymphazurin vs. 1% methylene blue in sentinel lymph node mapping of gastrointestinal tumors. Ann Surg Oncol. 2009;16:2224–30.PubMedCrossRef
26.
O’Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186:423–7.PubMedCrossRef
Metadata
Title
Selective Sentinel Lymph Node Dissection for Melanoma: Importance of Harvesting Nodes with Lower Radioactive Counts without the Need for Blue Dye
Authors
Liang-Chih Liu, MD
Brian M. Parrett, MD
Tyler Jenkins, BA
Wayne Lee, MD
Eugene Morita, MD
Patrick Treseler, MD
Laura Huang, BS
Suresh Thummala, MD
Robert E. Allen, MD
Mohammed Kashani-Sabet, MD
Stanley P. L. Leong, MD
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1689-0

Other articles of this Issue 10/2011

Annals of Surgical Oncology 10/2011 Go to the issue

Healthcare Policy and Outcomes

The Significance of PITX2 Overexpression in Human Colorectal Cancer

Thoracic Oncology

EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy

Breast Oncology

Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution

Head and Neck Oncology

Long-Term Experience in Sentinel Node Biopsy for Early Oral and Oropharyngeal Squamous Cell Carcinoma

Head and Neck Oncology

Low-Dose Preoperative Chemoradiation Therapy Compared with Surgery Alone with or Without Postoperative Radiotherapy in Patients with Head and Neck Carcinoma

Endocrine Tumors

What is the Added Benefit of Cervical Ultrasound to 99mTc-Sestamibi Scanning in Primary Hyperparathyroidism?